J&J Suggests Targeting OTC Monograph With Public-Private Initiative
This article was originally published in The Tan Sheet
Executive Summary
An FDA guidance provides the framework for J&J consumer business executives’ suggestions to improve the OTC drug review. A public-private partnership “is key to developing and delivering a comprehensive solution,” says Lynne Szczepaniak, regulatory affairs VP at J&J’s McNeil Consumer Healthcare subsidiary.